By Fineline Cube 
Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues of USD 15.0 billion, representing 1% year-over-year operational growth. Launched and Acquired Products grew 18%, while revenues excluding Comirnaty and Paxlovid increased 5% operationally. The company raised its full-year 2026 revenue guidance by USD 500 million at the midpoint to a range of USD 60.5 to USD 62.5 billion.
Financial Performance Snapshot
| Metric | Q2 2026 | YoY Change (Operational) | Full-Year 2026 Guidance |
|---|---|---|---|
| Total Revenue | USD 15.0B | +1% | USD 60.5–62.5B (+$500M midpoint increase) |
| Global Biopharmaceuticals | USD 14.661B | +1% | Not disclosed |
| Launched & Acquired Products | Not disclosed | +18% | Key growth driver |
| Ex-Comirnaty/Paxlovid Revenue | Not disclosed | +5% | Core business momentum |
Growth Portfolio Performance
Cardiovascular Leadership
- Eliquis (apixaban): USD 2,425M (+19% YoY)
- Primary driver: Higher net price in U.S. due to pricing dynamics
- Partnership: Co-commercialized with Bristol Myers Squibb
- Indication: Anticoagulation therapy
Oncology Expansion
- Padcev (enfortumab vedotin): USD 667M (+23% YoY)
- Primary drivers:
- Increased market share in first-line locally advanced/metastatic urothelial cancer (la/mUC)
- Launch uptake in cisplatin-ineligible muscle-invasive bladder cancer indication
- Origin: Seagen-developed antibody-drug conjugate (ADC)
- Lorbrena (lorlatinib): USD 354M (+37% YoY)
- Primary driver: Increased patient share in first-line ALK-positive metastatic NSCLC (ALK+ mNSCLC)
- Indication: Targeted therapy for lung cancer
Rare Disease Franchise
- Vyndaqel Family (Vyndaqel, Vyndamax, Vynmac): USD 1,762M (+8% operational)
- Primary drivers: Strong demand and improved access across international markets
- Indication: Transthyretin amyloid cardiomyopathy (ATTR-CM)
Strategic Business Dynamics
Portfolio Transition Success
- COVID-19 Impact: Decline in Comirnaty and Paxlovid revenues partially offset by strong growth in core portfolio
- Acquisition Integration: Launched and Acquired Products delivering 18% growth demonstrates successful integration strategy
- Diversification Benefit: Balanced exposure across cardiovascular, oncology, and rare disease therapeutic areas
Commercial Excellence
- Pricing Power: Eliquis demonstrating strong pricing dynamics in U.S. market
- Market Share Gains: Padcev and Lorbrena showing significant competitive positioning improvements
- Global Expansion: Vyndaqel family benefiting from international market access improvements
Forward Guidance & Strategic Outlook
Revised Full-Year Expectations
- Revenue Guidance: Raised by USD 500 million at midpoint to USD 60.5–62.5 billion
- Confidence Signal: Upward revision reflects strong H1 performance and positive H2 outlook
- Core Business Strength: 5% ex-COVID growth validates sustainable business model
Growth Catalysts
- Oncology Pipeline: Continued expansion of ADC and targeted therapy portfolios
- Cardiovascular Dominance: Eliquis maintaining leadership position with pricing power
- Rare Disease Leadership: Vyndaqel franchise demonstrating sustained global demand
- Integration Benefits: Full-year contribution from recent acquisitions expected to accelerate
Market Positioning
- Portfolio Resilience: Successful navigation of COVID-19 revenue decline through diversified growth drivers
- Innovation Focus: Strategic emphasis on high-value therapeutic areas with premium pricing potential
- Global Reach: International market expansion providing additional growth vectors beyond U.S. dominance
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, market dynamics, and strategic initiatives. Actual results may differ due to risks including competitive pressures, regulatory changes, market access challenges, and economic conditions.-Fineline Info & Tech